« Home « Kết quả tìm kiếm

Adjuvant therapy


Tìm thấy 20+ kết quả cho từ khóa "Adjuvant therapy"

Relevance of the time interval between surgery and adjuvant radio (chemo) therapy in HPV-negative and advanced head and neck carcinoma of unknown primary (CUP)

tailieu.vn

Kaplan-Meier estimates of overall survival according to the implementation of adjuvant therapy within (<. For head and neck cancer, Chen et al. recommend the im- plementation of adjuvant therapy within six weeks after surgery, although head and neck cancer of unknown pri- mary was not explicitly reviewed [20]. 42 days) but still improved survival regardless of the HPV-status (HR 1.06.

Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: A real-world study

tailieu.vn

Effec- tiveness of an adjuvant chemotherapy regimen for early-stage breast Cancer: a systematic review and Network Meta-analysis. Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?. Progress in adjuvant chemotherapy for breast cancer: an overview. Anthracycline versus nonanthra- cycline adjuvant therapy for early breast cancer: A systematic review and meta-analysis. Anthracycline vs nonanthracycline adju- vant therapy for breast cancer.

Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary P36

tailieu.vn

Pre-transplant neo-adjuvant therapy, most commonly using chemo-embolization, has been reported in several series but, to date, there have been no randomized controlled trials to support its routine use [53]. Following surgical resection and ablation, tumour recurrence and/or de novo tumour formation is common and adjuvant therapy has been investigated in the form of systemic therapy, hepatic arterial treatment, radiopharmaceuticals and immunotherapy.

Adjuvant immunotherapy recommendations for stage III melanoma: Physician and nurse interviews

tailieu.vn

Physicians and nurses verbalised difficulty determining the efficacy of adjuvant treatment in an individual be- cause there was no visible disease to follow, nor is there a specific biomarker to identify benefits from adjuvant therapy. Results suggest physicians’ and nurses’ primary concerns when recommending adjuvant immunotherapy to pa- tients with resected stage III melanoma were clinical and patient factors, such as melanoma sub-stage and an indi- vidual’s treatment risk/benefit profile.

The ideal approach for treatment of cT1N+ and cT2Nany esophageal cancer: A NCDB analysis

tailieu.vn

Patients who received adjuvant radiotherapy alone after surgery was associated with a decreased overall survival when compared to both adjuvant chemotherapy( p =0.005) and adjuvant chemoradiation( p =0.01). We also found significantly higher 30 and 90 day mortality in the NT group than that in the AT and the CT groups.. NT: Neoadjuvant therapy. AT: Adjuvant therapy. CT: Combination therapy of neoadjuvant and adjuvant.

Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: A retrospective control study

tailieu.vn

We expect more studies in the future to provide high-level evidence of the optimal duration of adjuvant chemotherapy in GC.. GC: Gastric cancer. https://doi.org/10.3322/caac.21492.. https://doi.org/10.21147/j.issn . Adjuvant therapy for gastric cancer:. https://doi.org/10.1200/JCO . Stemmermann GN, et al. https://doi.org/10.1056/. https://doi.org/10.1056/NEJMoa055531.. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al.

Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary P37

tailieu.vn

Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Lee CC, Yu MC, Hu RH, Peng CY, Lai KL, Chang SS, Chen PJ (2009) Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage.

Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary P1

tailieu.vn

Recent results in HCC strongly support that similar expectations might be achieved to improve outcome by including neoadjuvant or adjuvant therapy.. Hepatocellular carcinoma (HCC) is a major cause of cancer mortality world- wide. Understanding of the etiology, epidemiology, pathophysiology, molecular biology, and clinical features of HCC is important in providing optimal patient care.

The result of adjuvant vinorelbine plus cisplatin in completely resected stage IB-IIIA non-small cell lung cancer at Hanoi Medical University Hospital

tailieu.vn

Phase III trials have demonstrated the advantages of a combination regimen of Vinorelbine with cisplatin in adjuvant therapy in patients with NSCLC that have shown to prolong disease-free survival as well as overall survival [5 - 7]. Due to its effectiveness and superiority, Vinorelbine - Cisplatin regimen has become an accepted regimen in the world and in Vietnam in adjuvant treatment of NSCLC..

Hepatocellular Carcinoma: Targeted Therapy and Multidisciplinary P25

tailieu.vn

Roayaie S, Frischer JS, Emre SH et al (2002) Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Graziadei IW, Sandmueller H, Waldenberger P et al (2003) Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.

Chapter 090. Bladder and Renal Cell Carcinomas (Part 4)

tailieu.vn

Similar results were obtained in an international study of three cycles of cisplatin, methotrexate, and vinblastine (CMV) followed by either radical cystectomy or radiation therapy. The decision to administer adjuvant therapy is based on the risk of recurrence after cystectomy. Indications for adjuvant chemotherapy include the presence of nodal disease, extravesical tumor extension, or vascular invasion in the resected specimen.

Chapter 083. Cancer of the Skin (Part 6)

tailieu.vn

SLNB is of value in selecting patients who may benefit from adjuvant therapy. Survival benefit of SLNB remains to be proven.. Adjuvant Therapy for Nodal Disease. For patients who are free of disease but at high risk for metastases, adjuvant therapy that complements surgery is needed to destroy occult micrometastases, prolong disease-free survival, and improve the cure rate. of improving disease-free and overall survival in patients with nodal metastases (stage III disease).

Chapter 093. Gynecologic Malignancies (Part 4)

tailieu.vn

Patients with stage I disease, no residual tumor, and well or moderately differentiated tumors need no adjuvant therapy after definitive surgery, and 5-year survival exceeds 95%. For all other patients with early disease and those stage I patients with poor prognosis histologic grade, adjuvant platinum-based therapy is warranted. For patients with advanced (stage III) disease but with limited or no residual disease after definitive cytoreductive surgery (about half of all stage III.

Chapter 087. Gastrointestinal Tract Cancer (Part 17)

tailieu.vn

Moertel CG et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. O'Connell JB et al: Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. O'Connell MJ et al: Improving adjuvant therapy for rectal cancer by combining protracted infusion fluorouracil with radiation therapy after curative surgery.

Nitric oxide in occurrence, progress and therapy of lung Cancer: A systemic review and meta-analysis

tailieu.vn

Clinical and serological responses to Bufeihuayu decoction adjuvant therapy in patients with non-small cell lung Cancer. Exhaled breath analysis: novel approach for early detection of lung cancer. Lung Cancer. Nitric oxide and aggressive behavior of lung Cancer cells. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

Chapter 086. Breast Cancer (Part 9)

tailieu.vn

One approach—so-called neoadjuvant chemotherapy—involves the administration of adjuvant therapy before definitive surgery and radiation therapy.. Because the objective response rates of patients with breast cancer to systemic therapy in this setting exceed 75%, many patients will be "downstaged". However, overall survival has not been improved using this approach..

Demographic, tumour, and treatment characteristics of female patients with breast cancer in Sri Lanka; results from a hospital-based cancer registry

tailieu.vn

Concordance between guideline recommendations for use of adjuvant therapy for non-metastatic breast cancer and actual rates of delivery of such adjuvant therapies for patients is noted in Table 3. Rate of chemotherapy delivery (neoadjuvant or adjuvant) was 91% for women with node positive breast cancer. Endo- crine therapy has been initiated in 88% of women with hormone receptor positive breast cancer while rate of trastuzumab use was 59% among women with HER2 positive breast cancer..

The importance of choosing the right strategy to treat small cell carcinoma of the cervix: A comparative analysis of treatments

tailieu.vn

Of the 15 patients with upfront surgery, eleven patients received adjuvant therapy with an SCCC regimen: four had CCRT with an EP regimen and seven had chemotherapy with an EP (n = 4) or IP (n = 3) regimen. Four patients who had adjuvant therapy with a non-SCCC regimen were treated with concurrent radiotherapy, but all of them died from metastasis of SCCC.

Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2- negative breast cancer: A randomized pilot trial

tailieu.vn

Moreover, this trial is the first study to provide valuable clinical data of the impact of everolimus plus letrozole which was applicated as new adjuvant therapy on peripheral blood immune cell subsets in postmenopausal ER-positive/HER2-negative patients.

Chapter 087. Gastrointestinal Tract Cancer (Part 13)

tailieu.vn

Patients with stage II tumors do not appear to benefit from adjuvant therapy. rectal cancer, the delivery of preoperative or postoperative combined modality therapy (5-FU plus radiation therapy) reduces the risk of recurrence and increases the chance of cure for patients with stages II and III tumors, with the preoperative approach being better tolerated